Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Interestingly, of those who received anti-osteoporosis medication within 1 year after their hip fracture, only 13% had not received BMD testing, while 87% had DXA results (P < 0.001).Key indices of patients at discharge and at the 1: and 3-year follow-upsKey performance indicesDischarge (n = 476)1-year post-fracture (n = 421)3-year post-fracture (n = 389)Rate of BMD assessment*397 (81.2%)Rate of calcium and vitamin D supplementation468 (98.3%)391 (92.8%)352 (90.5%)Rate of treatment with anti-osteoporosis medication64 (13.4%)171 (40.6%)153 (39.3%) Oral bisphosphonate37 (7.8%)114 (27.1%)98 (25.2%) Intravenous bisphosphonate7 (1.5%)10 (2.4%)6 (1.5%) Denosumab13 (2.7%)42 (10.0%)44 (11.3%) Teriparatide5 (1.1%)4 (1.0%)5 (1.3%) Strontium ranelate**2 (0.4%)1 (0.2%)0 (0%)Post-fracture ambulatory status Bedridden47 (9.9%)47 (11.2%)34 (8.7%) Indoor ambulator364 (76.5%)101 (24.0%)129 (33.2%) Outdoor ambulator65 (13.7%)273 (64.8%)226 (58.1%)Rate of refracture*0 (0.0%)8 (1.6%)28 (5.7%)*The rates were calculated based on the total of 489 FHF patients enrolled in this study**Strontium ranelate has not been available since 2017

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

These patients were excluded since their prognoses differ from those of patients with an osteoporotic fracture.Patients who sustained multiple injuries or fractures.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Three-year outcomes of a fracture liaison service model at a university-based tertiary care hospital in Thailand

Study design awaiting verification · Archives of Osteoporosis · 2023

Original publication title

Three-year outcomes of a fracture liaison service model at a university-based tertiary care hospital in Thailand

Pojchong Chotiyarnwong; Nitchanant Kitcharanant; Ekasame Vanitcharoenkul; Chirathit Anusitviwat; Atthakorn Jarusriwanna; Worasit Suthutvoravut; Wararat Boonnasa; Aasis Unnanuntana

© The Author(s) 2023

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

This study confirms the benefits of having a multidisciplinary FLS care team to manage older people with FHF. An FLS improves the care of patients with FHF and the social support of caregivers and relatives. The FLS maintained the functional outcomes of the patients through 3 years of postfracture treatment.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

This study assessed the 3-year outcomes after fragility hip fracture (FHF) treatment by a multidisciplinary team from the Siriraj Fracture Liaison Service (Si: FLS). The review investigated the administration rates of anti-osteoporosis medication, refracture, and mortality; activities of daily living; mobility; and health-related quality of life.

Source: Purpose

Abstract: What methods does the paper describe?

A retrospective review was performed of the records of Si-FLS patients given FHF treatment between June 2016 and October 2018. The outcomes were evaluated at 3 time points: before discharge, and 1 and 3 years after treatment.

Source: Methods

Abstract: Summary

Fragility hip fracture (FHF) is a serious complication of osteoporosis. A fracture liaison service (FLS) is crucial in preventing FHF. Our retrospective data of 489 patients with FHF and 3-year follow-ups demonstrated that the FLS improved functional outcomes. Our study’s mortality rates were lower than in other published series.

Source: Summary

Abstract: Results

The study enrolled 489 patients (average age, 78). The mortality and refracture rates at 1 year after hip fracture were 13.9% and 1.6%, respectively. At the 3-year follow-up, both rates were higher (20.4% and 5.7%, respectively). The Barthel Index and EuroQoL Visual Analogue Scale had risen to a plateau at the 1-year follow-up and remained stable to the 3-year follow-up. One year after treatment, approximately 60% of the patients could ambulate outdoors, and the proportion remained steady until the 3-year follow-up.

There was no difference in the 1: and 3-year follow-up anti-osteoporosis medication administration rates (approximately 40%).

Source: Results

Abstract: Conclusions

This study confirms the benefits of having a multidisciplinary FLS care team to manage older people with FHF. An FLS improves the care of patients with FHF and the social support of caregivers and relatives. The FLS maintained the functional outcomes of the patients through 3 years of postfracture treatment.

Source: Conclusions
Authors’ abstract

Abstract 

Summary

Fragility hip fracture (FHF) is a serious complication of osteoporosis. A fracture liaison service (FLS) is crucial in preventing FHF. Our retrospective data of 489 patients with FHF and 3-year follow-ups demonstrated that the FLS improved functional outcomes. Our study’s mortality rates were lower than in other published series.

Purpose

This study assessed the 3-year outcomes after fragility hip fracture (FHF) treatment by a multidisciplinary team from the Siriraj Fracture Liaison Service (Si: FLS). The review investigated the administration rates of anti-osteoporosis medication, refracture, and mortality; activities of daily living; mobility; and health-related quality of life.

Methods

A retrospective review was performed of the records of Si-FLS patients given FHF treatment between June 2016 and October 2018. The outcomes were evaluated at 3 time points: before discharge, and 1 and 3 years after treatment.

Results

The study enrolled 489 patients (average age, 78). The mortality and refracture rates at 1 year after hip fracture were 13.9% and 1.6%, respectively. At the 3-year follow-up, both rates were higher (20.4% and 5.7%, respectively). The Barthel Index and EuroQoL Visual Analogue Scale had risen to a plateau at the 1-year follow-up and remained stable to the 3-year follow-up. One year after treatment, approximately 60% of the patients could ambulate outdoors, and the proportion remained steady until the 3-year follow-up.

There was no difference in the 1: and 3-year follow-up anti-osteoporosis medication administration rates (approximately 40%).

Conclusions

This study confirms the benefits of having a multidisciplinary FLS care team to manage older people with FHF. An FLS improves the care of patients with FHF and the social support of caregivers and relatives. The FLS maintained the functional outcomes of the patients through 3 years of postfracture treatment.

Publication and source details

Original title: Three-year outcomes of a fracture liaison service model at a university-based tertiary care hospital in Thailand

Pojchong Chotiyarnwong; Nitchanant Kitcharanant; Ekasame Vanitcharoenkul; Chirathit Anusitviwat; Atthakorn Jarusriwanna; Worasit Suthutvoravut; Wararat Boonnasa; Aasis Unnanuntana

Archives of Osteoporosis · 2023

© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T20:51:10.170142+00:00

DOI: 10.1007/s11657-023-01215-z · PMC9873743